Key Findings
The Phase 1/2a BLUESTAR study reported that AZD8205 induced partial responses in patients with advanced or metastatic ovarian, endometrial, and breast cancers. Among the 44 patients treated at doses of 1.6 milligrams per kilogram or higher—the predicted efficacious exposure range—the objective response rate was 20.5%, with 9 patients achieving a partial response. The trial included 47 patients with B7-H4-positive solid tumors who had previously undergone treatment.
Technical Details
AZD8205, also known as puxitatug samrotecan, is an antibody-drug conjugate that pairs a B7-H4-directed antibody with a topoisomerase-1 inhibitor payload via a stable cleavable linker. This architecture enables the release of the cytotoxic payload within B7-H4-expressing cells and provides a bystander effect on adjacent tumor cells. In the trial, the drug was administered intravenously every three weeks at doses between 0.8 and 3.2 milligrams per kilogram.
Safety data indicated that the most frequent treatment-related adverse events were nausea (51.1%), neutropenia (48.9%), and anemia (38.3%). Dose-limiting neutropenia and thrombocytopenia were observed at the highest dose of 3.2 milligrams per kilogram, defining the upper limit of tolerability.
Background and Context
B7-H4 is a protein highly expressed in various solid tumors but limited in normal tissue. It contributes to tumor progression by negatively regulating T-cell function, making it a strategic target for targeted therapy. Translational analyses from the trial confirmed the selective localization of the topoisomerase-1 inhibitor to B7-H4-expressing cells and the subsequent induction of target-dependent DNA damage.
Significance and Outlook
These results provide the first clinical proof of concept for B7-H4 as an ADC target. The response signals are particularly significant given that the study population consisted of heavily pretreated patients. While the trial was primarily designed for safety and dose identification rather than definitive efficacy, the manageable toxicity profile and mechanistic evidence support further development to refine dosing and expand testing across other B7-H4-positive malignancies.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
